Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Exercise echo may catch silent heart failure in rare HHT liver disease

NCT ID NCT05954481

Knowledge-focused Sponsor: Hospices Civils de Lyon Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed pilot study looked at 47 adults with hereditary hemorrhagic telangiectasia (HHT) who also have liver involvement. Researchers used exercise echocardiography (heart ultrasound while pedaling) to measure lung artery pressure during exercise. The goal was to see if this test could detect early signs of heart failure before they show up at rest, potentially helping doctors decide when to consider advanced treatments like liver transplantation.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
stress echocardiography
What this could lead to
If successful, this could lead to earlier detection of heart failure in HHT patients, potentially improving timing for treatments like liver transplantation.
What could go wrong
This is a small pilot study with only 47 participants, so results may not apply to all patients. It is observational and does not test a new treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

47 people

The number who actually took part.

Started

Aug 2023

Finished

Jan 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * HHT patient \> 18 yo * Hepatic involvement (hepatic artery diameter \> 6mm) * Patient having received the information and signed the informed consent form * Patient affiliated to a social security scheme or beneficiaries of a similar scheme Exclusion Criteria: * Haemoglobin \< 90 g/L * Active Infection * Atrial Fibrillation permanent or persistent * Known cardiopathy * Pregnant or breastfeeding woman (by questioning) * Adult subject to a legal protection measure (guardianship) * Participation in another clinical trial that may interfere with the proposed trial (investigator judgment) * Patient physically unable to pedal * Patient with Pulmonary arteriovenous malformations awaiting embolization * Patient treated with beta-blockers Secondary Exclusion Criteria verified on rest ultrasound * PAH (Pulmonary Arterial Hypertension) at rest (Vmax \> 2.8 m/sec) * Inability to obtain a stream of IT at rest * Patient with atrial fibrillation (AF)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hereditary hemorrhagic telangiectasia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hereditary hemorrhagic telangiectasia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hereditary hemorrhagic telangiectasia Rendu osler disease

Contacts and locations

Locations

  • Service Explorations fonctionnelles cardiovasculaires - Hôpital Louis Pradel

    Bron, 69677, France

  • Service génétique - Hôpital Femme Mère Enfant

    Bron, 69677, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.